Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Insulin glargine biosimilar (Abasaglar®)

Brand: Abasaglar®
Indication: Type 1 and Type 2 diabetes mellitus
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No


Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Biosimilars of insulin glargine 100 units/mL (Lantus®) are recommended for use in patients with type 1 and type 2 diabetes mellitus. The prescribing of biosimilar preparations should be by brand name, followed by the concentration and recommended daily dose in units and a statement of the formulation. Treatment should normally be started with the least expensive drug.
The initiation of biosimilar insulins should be in NEW patients or patients assessed to need a medication change, with close monitoring of their blood glucose to ensure good control is achieved.
The LMMG recommends Abasaglar KwikPen® as the 1st line long-acting insulin analogue.


LMMG recommendation: Green
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

Algorithm For Antihyperglycaemic Therapy In Adults With Type II V1.5 (467.6 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG